CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Relation between baseline plaque features and subsequent coronary artery remodeling determined by optical coherence tomography and intravascular ultrasound From organic and inorganic phosphates to valvular and vascular calcifications Discrepancies in Measurement of the Thoracic Aorta: JACC Review Topic of the Week Long-term outcome of prosthesis-patient mismatch after transcatheter aortic valve replacement Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors Utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention for type C lesions Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Intravascular ultrasound guidance improves clinical outcomes during implantation of both first- and second-generation drug-eluting stents: a meta-analysis Chimney technique in a TAVR-in-TAVR procedure with high risk of left main artery ostium occlusion INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction

Review Article2018 Jun 13.[Epub ahead of print]

JOURNAL:Eur Heart J. Article Link

Heart failure with preserved ejection fraction: from mechanisms to therapies

Lam CSP, Voors AA, de Boer RA et al. Keywords: HFpEF; mechanisms; therapy

ABSTRACT


This review aims to provide a translational perspective on recent developments in heart failure with preserved ejection fraction (HFpEF), linking mechanistic insights to potential therapies. A key concept in this review is that HFpEF is a haemodynamic condition wherein the heart fails to keep up with the circulatory demands of the body, or does so at the expense of raised left ventricular filling pressures. We, therefore, propose that the 'final common pathway' for development of congestion, i.e. basic haemodynamic mechanisms of increased left ventricular end-diastolic pressure, left atrial hypertension, pulmonary venous congestion, and plasma volume expansion, represents important initial targets for therapy in HFpEF. Accordingly, we group this review into six mechanisms translating into potential therapies for HFpEF: beginning with three haemodynamic mechanisms (left atrial hypertension, pulmonary hypertension, and plasma volume expansion), and working backward to three potential molecular mechanisms [systemic microvascular inflammation, cardiometabolic functional abnormalities, and cellular (titin)/extracellular (fibrosis) structural abnormalities].